IYH ETF

The iShares U.S. Healthcare ETF (IYH) is an exchange-traded fund that aims to give investors a wide range of access to the healthcare sector of the stock market. It was launched on June 12, 2000, and is managed passively.

This monthly report examines important industry statistics in the healthcare field. Currently, this sector is considered to be about 20% overvalued compared to the averages from the past 11 years. Among the different subsectors, healthcare providers are the least overvalued.

The iShares U.S. Healthcare ETF (IYH) is an exchange-traded fund that aims to give investors a wide range of access to the healthcare sector of the stock market. It is passively managed and was established on June 12, 2000.

Defensive sector ETFs are reaching new peaks as September begins slowly.

IYH invests in large-cap U.S. healthcare stocks with strong earnings growth potential. Despite trailing the S&P 500 index in the past year, healthcare stocks are expected to rebound strongly in 2024 and 2025 with better growth rates. Healthcare sector's valuation may be high compared to historical levels, but still lower than the dot-com bubble.

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (IYH), a passively managed exchange traded fund launched on 06/12/2000.

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (IYH), a passively managed exchange traded fund launched on 06/12/2000.

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the iShares U.S. Healthcare ETF (IYH) is a passively managed exchange traded fund launched on 06/12/2000.

iShares U.S. Healthcare ETF provides exposure to the healthcare sector, holding 120 healthcare-related stocks. Healthcare stocks have had varying performances in recent years, with winners and losers in the sector. The increasing prevalence of chronic diseases and longer lifespans present opportunities for drug companies but also risks such as increased scrutiny and regulation.